Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man

被引:102
作者
Matagne, A [1 ]
Klitgaard, H [1 ]
机构
[1] UCB SA, Pharma Sector, Preclin CNS Res, B-1420 Braine Alleud, Belgium
关键词
kindling; seizures; epilepsy; vigabatrin; levetiracetam; MK-801;
D O I
10.1016/S0920-1211(98)00016-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Epileptogenesis induced by electrical kindling of rats appears to be superior to the acute maximal electroshock seizure (MES) test in normal animals in predicting the efficacy and adverse effect potential of drugs in patients with partial epilepsy. Unfortunately, inclusion of such kindling models in primary screening is hampered by the laborious and expensive procedure of stimulation and recording with implanted brain electrodes. Furthermore the size of the rats excludes their use in initial testing where compound availability is often limited for the 'first batch synthesis'. The present study demonstrates that chronic electrical stimulation with corneal electrodes in mice can rapidly yield large numbers of kindled animals with a seizure phenomenology reflecting partial seizures in man. A pharmacological characterisation showed that corneally kindled mice can be used repeatedly for several drug experiments with reproducible results. The seizure protection and adverse effect potential obtained with proven antiepileptic drugs were similar to the effects observed in amygdala kindled rats and their corresponding clinical profile in partial epilepsy. Protection was obtained with vigabatrin and levetiracetam in this new model despite their lack of anticonvulsant activity in the acute MES test. Furthermore, in agreement with clinical findings with NMDA antagonists, MK-801 revealed more severe adverse effects in corneally kindled mice than in normal animals. These results suggest that corneal kindling of mice represents a sensitive and valid screening model for the identification of new therapies for partial epilepsy in man. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:59 / 71
页数:13
相关论文
共 20 条
[1]   CGP-37849 AND CGP-39551 - NOVEL AND POTENT COMPETITIVE N-METHYL-D-ASPARTATE RECEPTOR ANTAGONISTS WITH ORAL ACTIVITY [J].
FAGG, GE ;
OLPE, HR ;
POZZA, MF ;
BAUD, J ;
STEINMANN, M ;
SCHMUTZ, M ;
PORTET, C ;
BAUMANN, P ;
THEDINGA, K ;
BITTIGER, H ;
ALLGEIER, H ;
HECKENDORN, R ;
ANGST, C ;
BRUNDISH, D ;
DINGWALL, JG .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 99 (04) :791-797
[2]   A PERMANENT CHANGE IN BRAIN FUNCTION RESULTING FROM DAILY ELECTRICAL STIMULATION [J].
GODDARD, GV ;
MCINTYRE, DC ;
LEECH, CK .
EXPERIMENTAL NEUROLOGY, 1969, 25 (03) :295-&
[3]   VIGABATRIN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN EPILEPSY AND DISORDERS OF MOTOR CONTROL [J].
GRANT, SM ;
HEEL, RC .
DRUGS, 1991, 41 (06) :889-926
[4]   KINDLING INCREASES THE SENSITIVITY OF RATS TO ADVERSE-EFFECTS OF CERTAIN ANTIEPILEPTIC DRUGS [J].
HONACK, D ;
LOSCHER, W .
EPILEPSIA, 1995, 36 (08) :763-771
[5]   COMPREHENSIVE OBSERVATIONAL ASSESSMENT .IA. A SYSTEMATIC QUANTITATIVE PROCEDURE FOR ASSESSING BEHAVIORAL AND PHYSIOLOGIC STATE OF MOUSE [J].
IRWIN, S .
PSYCHOPHARMACOLOGIA, 1968, 13 (03) :222-&
[6]   ANTIEPILEPTIC DRUG DEVELOPMENT PROGRAM - A COOPERATIVE EFFORT OF GOVERNMENT AND INDUSTRY [J].
KUPFERBERG, HJ .
EPILEPSIA, 1989, 30 :S51-S56
[7]   IS AMYGDALA KINDLING IN RATS A MODEL FOR DRUG-RESISTANT PARTIAL EPILEPSY [J].
LOSCHER, W ;
JACKEL, R ;
CZUCZWAR, SJ .
EXPERIMENTAL NEUROLOGY, 1986, 93 (01) :211-226
[8]   WHICH ANIMAL-MODELS SHOULD BE USED IN THE SEARCH FOR NEW ANTIEPILEPTIC DRUGS - A PROPOSAL BASED ON EXPERIMENTAL AND CLINICAL CONSIDERATIONS [J].
LOSCHER, W ;
SCHMIDT, D .
EPILEPSY RESEARCH, 1988, 2 (03) :145-181
[9]  
LOSCHER W, 1991, J PHARMACOL EXP THER, V256, P432
[10]   STRATEGIES IN ANTIEPILEPTIC DRUG DEVELOPMENT - IS RATIONAL DRUG DESIGN SUPERIOR TO RANDOM SCREENING AND STRUCTURAL VARIATION [J].
LOSCHER, W ;
SCHMIDT, D .
EPILEPSY RESEARCH, 1994, 17 (02) :95-134